secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0000882095-23-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q1: ex-Veklury product sales +15% to $5.7B; lowers GAAP EPS guidance to $4.75-$5.15
--------------------------------------------------------------------------------

- Q1 total revenue $6.4B (-4% YoY); product sales ex-Veklury up 15% to $5.7B.
- HIV sales $4.2B (+13%); Biktarvy sales $2.7B (+24%); Oncology sales $670M (+59%).
- Non-GAAP diluted EPS $1.37 vs $2.12 YoY; GAAP EPS $0.80 vs $0.02.
- GAAP EPS guidance lowered to $4.75-$5.15 from $5.30-$5.70; non-GAAP unchanged $6.60-$7.00.
- Cash & equivalents $7.2B; paid $969M dividends, repurchased $400M stock in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/0000882095-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/gild-20230427.htm
  HTML page:      https://secwatch.observer/filing/0000882095-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer